A 47-year-old woman walks into the office having gained 22 pounds over four years despite eating less than she did at 35 and walking five days a week. Her primary care doctor told her it was "just menopause" and recommended she try harder. Her labs show fasting insulin of 18, hs-CRP of 4.1, low free testosterone, suboptimal free T3, and a waist circumference that has crept past the threshold for visceral adiposity. The story she has been told — that her weight gain is a willpower problem — is wrong. What is actually happening is that her fat tissue has stopped behaving like inert storage and started behaving like a malfunctioning endocrine organ.
I see this almost every week, and the framing matters because it changes what works.
Adipose tissue is not passive — it is a secretory organ
For decades the medical training I went through treated fat as a metabolic afterthought. Calories in, calories out, fat as the savings account. That model is not just incomplete; for mid-life patients it is actively misleading. Adipose tissue — particularly visceral adipose tissue, the fat that wraps around abdominal organs — secretes more than 50 identified signaling molecules called adipokines. Leptin, adiponectin, resistin, TNF-alpha, IL-6, and PAI-1 are the ones I track most often, because they show up in the labs and they explain the symptoms.
When fat mass expands beyond a certain individual threshold, the secretion profile changes. Adiponectin (which improves insulin sensitivity and is anti-inflammatory) drops. Leptin rises but the brain becomes resistant to it, so satiety signaling fails. TNF-alpha and IL-6 rise, producing low-grade chronic inflammation that you can see on hs-CRP and ferritin. This inflammatory output drives further insulin resistance in liver and muscle, which traps the body in a fat-storage state regardless of caloric intake. The fat tissue, in other words, is sending signals that make it harder to lose fat tissue. It is a self-perpetuating loop, and it is mechanical, not behavioral.
Visceral fat is the worst offender. Subcutaneous fat — the fat under the skin on the hips and thighs — is metabolically quieter. Visceral fat sits in direct portal circulation with the liver and dumps free fatty acids and inflammatory cytokines straight into the hepatic system. That is why waist circumference predicts cardiometabolic risk better than BMI does, and why two patients at the same weight can have completely different metabolic pictures.
Why "eat less, move more" stops working in mid-life
When I evaluate someone who has gained weight in their 40s or 50s despite eating reasonably and exercising, I am almost always looking at the same cluster: declining sex hormones, rising cortisol, suboptimal thyroid conversion, insulin resistance, and inflammatory adipokine output. These mechanisms reinforce each other. Estrogen decline in women shifts fat distribution toward the abdomen. Testosterone decline in men reduces lean muscle mass, which lowers resting metabolic rate by 50-100 calories a day per pound of muscle lost. Cortisol from chronic sleep deprivation directly promotes visceral fat storage. Insulin resistance suppresses fat oxidation. The fat tissue itself is then secreting inflammatory signals that worsen all of the above.
Telling that patient to eat 200 fewer calories is not wrong, exactly, but it is treating one variable in a five-variable equation, and the equation is rigged against them. A meaningful percentage of patients I see in the medical weight loss program have been doing exactly what they were told for years and have moved in the wrong direction anyway. Not because they are lying about adherence — they usually are not — but because the underlying physiology has tilted and conventional advice does not address the tilt.
How GLP-1 fits in — and what it does not solve
GLP-1 receptor agonists (semaglutide, tirzepatide) are the most useful pharmacologic tool we have right now for the patient population I am describing. They mimic an endogenous gut hormone, slow gastric emptying, suppress appetite at the hypothalamic level, and improve insulin sensitivity. Across study populations, semaglutide produces around 15% body weight loss over 68 weeks; tirzepatide produces around 21%. In my practice, the patients who match the typical responder profile — insulin-resistant, central adiposity, suboptimal hormones — usually do well on GLP-1 therapy.
But the medication addresses appetite and insulin sensitivity. It does not directly fix thyroid conversion, sex hormone decline, cortisol dysregulation, or the inflammatory profile of existing visceral fat. Patients whose program is GLP-1 alone often plateau around month four or five and regain when they stop, because the underlying drivers were never addressed. That is the failure pattern I see most often in patients who come to me after trying GLP-1 elsewhere.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
The version of the program that works runs GLP-1, where appropriate, alongside hormone optimization, thyroid support where indicated, and nutritional counseling that targets the inflammatory load. The point is to shrink visceral fat mass, which then shifts the adipokine profile, which then improves insulin sensitivity, which then makes it easier for the body to hold the loss after medication titration. The mechanisms cooperate when you address them in parallel.
What I look for in the workup
When a new patient comes in for medical weight loss, the lab panel I order is structured to find the drivers, not just confirm the BMI. Specifically:
- Fasting insulin and HOMA-IR — fasting glucose alone misses early insulin resistance. I want fasting insulin ideally under 7. Anything above 10 is a red flag regardless of glucose.
- HbA1c — the trailing three-month glucose picture.
- Full thyroid panel — TSH, free T3, free T4, reverse T3, and antibodies. TSH alone misses subclinical conversion problems that are common in chronic stress and chronic inflammation.
- Sex hormones — estradiol, progesterone, total and free testosterone, DHEA-S, SHBG. Mid-life weight gain is rarely separable from the sex hormone picture.
- hs-CRP and ferritin — inflammatory load. hs-CRP above 3 in someone without acute illness usually indicates the adipose-inflammatory loop is active.
- Leptin and adiponectin when the picture warrants it — these are the direct adipokine readouts.
- Lipid panel with apoB and Lp(a) — cardiovascular risk stratification, which my emergency medicine and cardiac ICU background will not let me ignore.
- Body composition — DEXA when available, waist circumference at minimum. BMI alone is not adequate.
The lab review visit is where the plan gets built. By that point you have the same data I do, and the conversation about which interventions match your specific physiology is grounded in numbers rather than guessing.
How the program runs at 90 days
The structured phase is 90 days because that is what it takes to complete the workup, initiate interventions, reassess at three months, and build the maintenance framework. The first 30 days are diagnostic clarity and conservative initiation — if GLP-1 is part of the plan, it starts at 0.25 mg weekly for semaglutide or the equivalent. Adjacent interventions layer in on a schedule the body can absorb. The middle 30 days are titration based on tolerance and response. Body composition gets reassessed at this point because what I want is fat loss, not muscle loss, and a scale alone cannot tell the difference. The final 30 days are optimization and maintenance planning. Labs re-run. Composition re-measured. The plan beyond day 90 is built deliberately rather than by default, because the most common failure mode in medical weight loss is starting strong and then losing the framework.
When this is not the right path
I turn away patients at the workup stage when the picture does not fit. Personal or family history of medullary thyroid carcinoma, MEN2 syndrome, or active pancreatitis are absolute contraindications to GLP-1. Patients with already-low BMI and athletic body composition rarely benefit. Patients whose primary problem is an undiagnosed eating disorder need a different intervention. And occasionally a patient's root cause is outside my scope — a referral to endocrinology or hepatology is the right answer in those cases, and I will tell you that rather than treat outside my lane.
The concrete next step
If you have been gaining weight in mid-life despite doing the things you used to do, the most useful next step is not another diet. It is a fasting insulin, an hs-CRP, a full thyroid panel, a sex hormone panel, and a waist measurement — followed by a real conversation about what those numbers mean for your physiology. Bring whatever prior labs you have, including any GLP-1 attempts and how your body responded. The intake at booking will route you to the right consultation type, and we can be seen at either the Columbus clinic or the Warner Robins clinic. Online booking is open 24/7. If you want to think it through first, the weight loss assessment is a five-minute self-screen that will tell you whether the pattern fits.
*Information in this article is educational and does not constitute medical advice. Consultation and lab work are required before any pharmacologic weight loss therapy is recommended. Individual results vary.*
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.